Substituted imidazopyridazines useful as kinase inhibitors

US8389527B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Brian E. Fink · Yardley, US
• Soong-Hoon Kim · Titusville, US
• Yufen Zhao · Pennington, US
• Ping Chen · San Diego, US
• Wayne Vaccaro · Yardley, US
• Litai H. Zhang · Lawrenceville, US
• Ashvinikumar V. Gavai · Princeton Junction, US
• Dharmpal S. Dodd · Princeton, US
• Libing Chen · Newtown, US

Key dates

• Filing date: Feb 6, 2009
• Grant date: Mar 5, 2013
• Expiry date: May 19, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compounds of formula Iand pharmaceutically acceptable salts thereof. The formula I imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.